Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin E2
AssigneePfizer Inc.
InventorsHuaZhu Ke, David D. Thompson
Life of this patent
Estimating the term…
Abstract
This invention is directed to pharmaceutical combination compositions and methods comprising (−)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt thereof and PGE2 or a pharmaceutically acceptable salt thereof, methods of using such compositions and kits containing such compositions. The compositions are useful for treating musculoskeletal frailty, including osteoporosis, osteoporotic fracture, low bone mass and frailty.
Claims22
A pharmaceutical composition comprising:
- in synergistic effective amounts
- a. a first compound, said first compound being (−)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt thereof;
- and
- b. a second compound, said second compound being PGE2 or a pharmaceutically acceptable salt thereof.
A method for treating a mammal suffering from musculoskeletal frailty comprising administering to said mammal
- a. a first compound, said first compound being (−)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt thereof;
- and
- b. a second compound, said second compound being PGE2 or a pharmaceutically acceptable salt thereof.
A kit comprising:
- a. (−)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent in a first unit dosage form;
- b. PGE2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent in a second unit dosage form;
- and
- c. a container.
Dependencies are inferred from the claim text.